Protocol Ledger

NCT06338995 · Phase III · RECRUITING

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Interventional Phase III clinical trial protocol NCT06338995 sponsored by Eli Lilly and Company in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-04-29 Enrollment: 510 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06338995
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)510 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06338995
Protocol FieldVerified Registry Value
NCT IdentifierNCT06338995
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment510 participants (ESTIMATED)
Registered Start Date2024-04-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI